{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:10:34Z","timestamp":1790683834667,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,18]]},"DOI":"10.7759\/cureus.75937","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T12:54:15Z","timestamp":1734526455000},"source":"Crossref","is-referenced-by-count":3,"title":["Intraocular Inflammation Following Intravitreal Faricimab Injection in Neovascular Age-Related Macular Degeneration"],"prefix":"10.7759","author":[{"given":"Shweta","family":"Parakh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrutanjoy","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priksha","family":"Lakhlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Important Safety Information | VABYSMO\u00ae (faricimab-svoa). vabysmo. Accessed. November 30, 2024: https:\/\/www.vabysmo-hcp.com\/important-safety-information.html.."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: The STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani AM","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, et al.. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: The STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020, 138:964-72. 10.1001\/jamaophthalmol.2020.2699","journal-title":"JAMA Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/24741264231220224","article-title":"Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS research and safety in therapeutics (ReST) committee","volume":"8","author":"Witkin AJ","year":"2024","unstructured":"Witkin AJ, Jaffe GJ, Srivastava SK, Davis JL, Kim JE. Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS research and safety in therapeutics (ReST) committee. J Vitreoretin Dis. 2024, 8:9-20. 10.1177\/24741264231220224","journal-title":"J Vitreoretin Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: Post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s J","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, et al.. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: Post hoc review of HAWK and HARRIER. Ophthalmology. 2021, 128:1050-9. 10.1016\/j.ophtha.2020.11.011","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.07.005","article-title":"Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration","volume":"125","author":"Daien V","year":"2018","unstructured":"Daien V, Nguyen V, Essex RW, Morlet N, Barthelmes D, Gillies MC. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology. 2018, 125:66-74. 10.1016\/j.ophtha.2017.07.005","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.0530","article-title":"Severe intraocular inflammation following intravitreal Faricimab","volume":"142","author":"Thangamathesvaran L","year":"2024","unstructured":"Thangamathesvaran L, Kong J, Bressler SB, et al.. Severe intraocular inflammation following intravitreal Faricimab. JAMA Ophthalmol. 2024, 142:365-70. 10.1001\/jamaophthalmol.2024.0530","journal-title":"JAMA Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1346322","article-title":"Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population","volume":"3","author":"Ibrahim FN","year":"2023","unstructured":"Ibrahim FN, Teo KY, Tan TE, et al.. Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population. Front Ophthalmol (Lausanne). 2023, 3:1346322. 10.3389\/fopht.2023.1346322","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.0928","article-title":"Association of occlusive retinal vasculitis with intravitreal faricimab","volume":"142","author":"Li Y","year":"2024","unstructured":"Li Y, Chong R, Fung AT. Association of occlusive retinal vasculitis with intravitreal faricimab. JAMA Ophthalmol. 2024, 142:489-91. 10.1001\/jamaophthalmol.2024.0928","journal-title":"JAMA Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2293925","article-title":"Uveitis following intravitreal injections of Faricimab: a case report","volume":"32","author":"Palmieri F","year":"2024","unstructured":"Palmieri F, Younis S, Bedan Hamoud A, Fabozzi L. Uveitis following intravitreal injections of Faricimab: a case report. Ocul Immunol Inflamm. 2024, 32:1873-7. 10.1080\/09273948.2023.2293925","journal-title":"Ocul Immunol Inflamm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420975303","article-title":"Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis","volume":"5","author":"Witkin AJ","year":"2021","unstructured":"Witkin AJ, Hahn P, Murray TG, et al.. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. J Vitreoretin Dis. 2021, 5:326-32. 10.1177\/2474126420975303","journal-title":"J Vitreoretin Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson WJ","year":"2021","unstructured":"Anderson WJ, da Cruz NF, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitreous. 2021, 7:37. 10.1186\/s40942-021-00307-7","journal-title":"Int J Retina Vitreous"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10050981","article-title":"Inflammatory complications of intravitreal anti-VEGF injections","volume":"10","author":"Cox JT","year":"2021","unstructured":"Cox JT, Eliott D, Sobrin L. Inflammatory complications of intravitreal anti-VEGF injections. J Clin Med. 2021, 10:10.3390\/jcm10050981","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000154","article-title":"Ocular inflammation associated with antivascular endothelial growth factor treatment","volume":"26","author":"Fine HF","year":"2015","unstructured":"Fine HF, Despotidis GD, Prenner JL. Ocular inflammation associated with antivascular endothelial growth factor treatment. Curr Opin Ophthalmol. 2015, 26:184-7. 10.1097\/ICU.0000000000000154","journal-title":"Curr Opin Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100862","article-title":"Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections","volume":"80","author":"Melo GB","year":"2021","unstructured":"Melo GB, Cruz NF, Emerson GG, et al.. Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections. Prog Retin Eye Res. 2021, 80:100862. 10.1016\/j.preteyeres.2020.100862","journal-title":"Prog Retin Eye Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling","volume":"52","author":"Liu L","year":"2011","unstructured":"Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011, 52:1023-34. 10.1167\/iovs.10-6431","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/323695-intraocular-inflammation-following-intravitreal-faricimab-injection-in-neovascular-age-related-macular-degeneration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T12:54:18Z","timestamp":1734526458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/323695-intraocular-inflammation-following-intravitreal-faricimab-injection-in-neovascular-age-related-macular-degeneration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.75937","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}